Dr. Pathak directs the Laboratory for Image-based Systems Biology, which works at the interface of engineering, medicine, and design to develop new hardware, software and “wetware” tools for basic and translational applications in tissue engineering and cancer. For the past several years he has collaborated with Dr. Grayson to spearhead the new field of “image-informed biomanufacturing” for tissue engineering applications. These efforts have included the development of novel in vivo and ex vivo imaging tools to acquire data to “inform” the design and deployment of more efficacious biomaterials for eventual clinical translation. More recently, he is collaborating with Dr. Grayson and other investigators to harness imaging and sensing technologies in health and disease models for applications in the Digital Twin (DT) and Precision Medicine (PM) space. Dr. Pathak has a long track record of leveraging in vitro, ex vivo, and in vivo imaging techniques for clinical biomarker development for cancer and other diseases. This includes multiscale imaging technologies and time-resolved characterization of disease evolution in vivo, all of which are critical for establishing the feasibility of DTs in the preclinical space. Dr. Pathak and his team are also leveraging cutting-edge miniaturized microscopy methods to characterize neurovascular changes longitudinally in preclinical models of brain aging. These approaches represent the first time that changes in multiple physiological variables can be measured continuously in vivo, over the lifetime of the aging model. These nascent studies have the potential to revolutionize our understanding of aging and its effects on the brain and other tissues. Finally, Dr. Pathak and his team are leveraging imaging-based artificial intelligence (AI) approaches to generate predictive models of engraftment success and biomaterial efficacy in vivo. Collectively, the imaging and computational tools that Dr. Pathak and his team are developing are synergistic with all the “Pillars” and “Horizontals” proposed in TTEC’s strategic plan for “Adaptive Therapeutics”, which make him an excellent fit as an affiliate faculty member of our Center.
Amer Riazuddin
I received PhD from the Department of Biochemistry and Molecular Biology, Johns Hopkins University School of Public Health (2002). Afterward, I completed two postdoctoral fellowships: first, at the National Eye Institute, National Institutes of Health, and second, at the McKusick-Nathans Institute of Genetic Medicine, here at Hopkins. Trained as an ocular geneticist, I have been involved in identifying the genetic basis of multiple inherited ocular diseases and understanding the underlying pathomechanism over the past two decades. In recent years, I have expanded the scope of my research to pluripotent stem cell-based regenerative medicine. Currently, my laboratory is validating stem cell-derived corneal endothelial cells as an alternative to donor tissue for the treatment of corneal endothelial dysfunction. Additionally, my laboratory is working on two research initiatives. First, the development of a non-surgical treatment of cataracts by perturbing lens cell pathways, and second, stem cell-based regeneration of the glaucomatous tissue as a possible treatment of glaucoma.
Gabsang Lee
Our group has been focusing on how we can utilize human induced pluripotent stem cells (iPSCs) to model neural and muscle diseases in a hope to develop new therapeutic strategies. My lab is one of the first teams who utilized human iPSCs for disease modelling and drug discovery/validation, and recently we developed new human iPSC-based cell therapies for degenerative diseases and aging.
Patrick Cahan
The Cahan Lab is a hybrid computational/experimental group that invents computational tools that distill omics data down to specific, testable hypotheses in the contexts of stem cell biology, developmental biology, and cell engineering. Most of our computational efforts are ‘single cell’ or spatial in nature, and thus this central part of our research fits with the ‘Single-cell/Spatial Transcriptomics’ theme of TTEC. Examples of computational platforms that we have created are 1. machine learning tools that measure the extent to which engineered cell populations reflect their natural counterparts, and 2. algorithms that predict the impact of cellular perturbations on cell engineered fidelity. Both of these applications can help to create and evaluate iPSC-derived disease models, which is another TTEC theme. Finally, we use these and other tools to uncover how cell lineages of the synovial joint emerge during development with the long term goal of leveraging this knowledge to engineer cells for regenerative medicine. This long-term goal aligns well with TTEC’s Tissue Engineering & Biomaterials Pillar and Healthy Aging theme.
Jonathan Schneck
Immunotherapy relies on the manipulation of the immune system to induce a potent and durable attack on diseased cells. T cells play an integral role in this by directing immune responses against infected or cancerous cells. My laboratory uses biomaterials to induce natural T cell responses for personalized cancer immunotherapy. This includes development of nanoparticle-based artificial antigen presenting cells (aAPC) that activate tumor-specific T cells targeting multiple tumor-specific targets. These tumor-specific T cells can be reintroduced in a process called adoptive cell transfer (ACT), resulting in persistent anti-tumor activity with immunologic memory. With recent advances the our lab has made aAPC that can also be used to transfer genetic material, such as CAR constructs to T cells. Additionally, using biocompatible platforms, we have synthesized an artificial lymph node (aLN) capable of activating T cells in vivo.
Collectively, our interests’ and tools are synergistic with the “Foundational Pillars” and “Cross-Cutting” themes in TTEC’s strategic plan for “Adaptive Therapeutics”, which make him an excellent fit for TTEC.





